Investigation of the myeloperoxidase index before and after non-M3 acute myeloid leukemia induction therapy

Abstract

The aim of this study was to evaluate the myeloperoxidase index before and after induction therapy of acute non-M3 myeloid leukemia as a predictive factor in assessing the prognosis of patients with this disease in Shahid Ghazi-Tabatabai Educational and Medical Center in Tabriz. Materials and Methods: In a retrospective cross-sectional study over a period of 6 years from 2013 to the end of 2019 in Shahid Ghazi Tabatabaei Educational, Therapeutic and Research Center of Tabriz, all patients with newly diagnosed AML subtype Non-M3 and were admitted to this center in the age range of 18 to 60 years in the specified period and did not receive the previous medication regimen for induction or other drug treatment interventions, were included in the study. Patients were studied for myeloperoxidase index before and after induction therapy until discharge. Based on remission, patients were divided into two groups and MPXI was recorded on the day before treatment, one week and 28 days later (to evaluate remission) and MPXI changes were compared between the two groups. Results:The mean age of patients was 51.02±15.04 years. Patients were evaluated in three treatment groups including 7+3 (Daunorubicin), 7+3 (Idarubicin) and 3Cytosar regimens. Most of the patients studied were M2 and then M4 subtypes. The final status of patients showed that only 30% of patients had remission at the end of induction therapy; The highest frequency of remission was observed in patients with M1 and M4 disease subtypes. Comparison of time periods between the three groups shows that in all three groups the mean MPXI increased significantly in the second time compared to the first time (p=0.001) and also significantly decreased in third time compared with the second time (p=0.001). The rate of decrease in MPXI values in the third time compared to the second time in the 7+3 (Daunorubicin) group was higher than other groups.